MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

Yasmina Bauer, Eric S. White, Simon de Bernard, Peter Cornelisse, Isabelle Leconte, Adele Morganti, Sebastien Roux, Oliver Nayler

Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016
Journal Issue: January
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Yasmina Bauer, Eric S. White, Simon de Bernard, Peter Cornelisse, Isabelle Leconte, Adele Morganti, Sebastien Roux, Oliver Nayler. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007

Endotrophin is related to disease progression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 4 (1) 00111-2016; 10.1183/23120541.00111-2016
Year: 2018



Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013

Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression.
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021


Plasma mitochondrial DNA as a biomarker of disease progression in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018



Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Never-smoking history as a poor prognostic factor in surgically proven idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013


Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent
Source: Eur Respir J, 55 (4) 1901519; 10.1183/13993003.01519-2019
Year: 2020



Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016


Correlation between physical activity and prognostic markers in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Is age a predictor in prognosis of patients with idiopathic pulmonary fibrosis?
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008

Pulmoanry hypertension is a negative prognostic factot of long term survival in patients with idiopathic pulmonary fibrosis after lung transplantation
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020

Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006

Evaluating disease severity in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017
Year: 2017



Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021


A simple prognostic tool for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018




IL-6 and IL-8 in stable and exacerbated IPF patients and their association to outcome
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016


Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008